Komori
Revision of earnings forecasts4516Nippon Shinyaku Co.,Ltd.Pharmaceuticals

2025年3月期 第2四半期(中間期)決算短信〔IFRS〕(連結)

2025年3月期の通期連結業績予想を上方修正した。売上収益、営業利益、税引前利益、親会社の所有者に帰属する当期利益のすべてを従来予想から引き上げている。

Worth reading
55In focus
0–100. This measures how worthwhile something is to read, not how good or bad the company is.
Direction
Improvement
Direction inferred from the company’s description.
Scale
3000
million yen
Wording
Avoiding a definitive answer
How definitive the wording is.

Revised forecast

Fiscal year ending March 2025 · Full yearPrevious forecast published 2024年8月7日
Net Sales154,000→157,000million yen
+1.9%
Operating profit32,000→33,000million yen
+3.1%
Profit attributable to owners of the parent29,000→30,000million yen
+3.4%
Net income per share430.57→445.24yen and sen
+3.4%

The bar length represents the relative magnitude of change, based on the item that changed the most in this document. The percentage change shown by the dotted line is calculated from the two reported figures because the company did not provide the rate.

Reason for the revision

「ウプトラビ」の海外売上に伴うロイヤリティ収入および「ビルテプソ」、「ビキセオス」等の新製品群の売上収益が前回発表予想を上回ったため。

Previous-period results売上収益:148,255百万円。通期の利益実績:Not disclosed
Dividend forecast revisionNo revision
Consolidated / non-consolidatedConsolidated
Revised forecast
ItemDetails
Net Sales154,000 million yen → 157,000 million yen(+1.9%)
Operating profit32,000 million yen → 33,000 million yen(+3.1%)
Profit attributable to owners of the parent29,000 million yen → 30,000 million yen(+3.4%)
Net income per share430.57 yen and sen → 445.24 yen and sen
Fiscal Period CoveredFiscal year ending March 2025
Period CoveredFull year
Publication date of previous forecast2024年8月7日
Previous-period results売上収益:148,255百万円。通期の利益実績:Not disclosed
Reason for the revision「ウプトラビ」の海外売上に伴うロイヤリティ収入および「ビルテプソ」、「ビキセオス」等の新製品群の売上収益が前回発表予想を上回ったため。
Dividend forecast revisionNo revision
Consolidated / non-consolidatedConsolidated
Items this document does not state (2)
Ordinary incomeDetails and amount of extraordinary loss

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

「ウプトラビ」の海外売上に伴うロイヤリティ収入、「ビルテプソ」、「ビキセオス」等の新製品群の売上収益が予想を上回ったため。

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.
2025年3月期 第2四半期(中間期)決算短信〔IFRS〕(連結) | Nippon Shinyaku Co.,Ltd. (4516) timely disclosure | Komori